/
With nearly two decades of helping clinicians manage chronic and other hard-to-heal wounds, MIMEDX provides a leading portfolio of products for applications in the wound care, burn, and surgical sectors of healthcare. The Company s vision is to be the leading global provider of healing solutions through relentless innovation to restore quality of life.
15.26% operating margin is respectable but not wide. ROIC at 18.59%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 20.0%, still solid.
ROIC dropped from 21.14% to 18.59%, capital efficiency is deteriorating.
Profitability & Returns
Revenue (TTM)
$389M
▲ +20.0% YoY
Net Income (TTM)
$31M
▲ +14.5% YoY
Op. Margin
10.17%
▼ -1.6pp YoY
ROIC
10.84%
▼ -2.5pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$71M
▲ +11.8% YoY
Net Debt
-$142M
Net Cash Position
Cash & Equiv.
$160M
5Y CAGR: +11.0%
Continue Research